"Viral Envelope Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
| Descriptor ID |
D014759
|
| MeSH Number(s) |
D12.776.964.970.880
|
| Concept/Terms |
Viral Envelope Proteins- Viral Envelope Proteins
- Proteins, Viral Envelope
- Virus Envelope Proteins
- Envelope Proteins, Virus
- Proteins, Virus Envelope
- Envelope Proteins, Viral
|
Below are MeSH descriptors whose meaning is more general than "Viral Envelope Proteins".
Below are MeSH descriptors whose meaning is more specific than "Viral Envelope Proteins".
This graph shows the total number of publications written about "Viral Envelope Proteins" by people in this website by year, and whether "Viral Envelope Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Envelope Proteins" by people in Profiles.
-
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathog. 2018 01; 14(1):e1006825.
-
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev. 2017 01; 275(1):217-229.
-
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
-
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol. 2009 Feb; 83(3):1240-59.
-
Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis. 1999 Nov; 180(5):1700-3.
-
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999 Jul 28; 282(4):331-40.